Boston Scientific 8-K

Summary

Boston Scientific leadership and operating-structure changes. Joe Fitzgerald becomes COO on 1/1/2027, overseeing global operations, business units and regions. The company will also establish three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, with the stated aim of speeding decisions and supporting growth. Mark Bickel becomes chief accounting officer on 3/1/2027, succeeding Emily Woodworth, who remains in the role until then.

Key Figures

• Fitzgerald compensation effective 1/1/2027: $1.05M annual base salary; annual bonus target of 110% of base salary; 2027 equity award with $7.0M grant-date fair value, expected in February, consisting of stock options and restricted stock units, including performance-based units, vesting 25% per year.
• Retirement plan benefit: potential lump sum of 2.5 months’ base salary per service year, capped at 36 months.

Investor Takeaways

• Watch the 1/1/2027 rollout of the new segments and operating model; Interventional Therapies is expected to include Penumbra following the anticipated acquisition close.